A Phase 1 Study of [ 14 C]-Ixazomib to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphoma
Latest Information Update: 27 Aug 2020
At a glance
- Drugs Ixazomib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 25 Aug 2020 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Results published in the Investigational New Drugs
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics